Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026

Adicet Bio, Inc.

2026-Q1 EPS reported -$1.88

Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.
Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.
Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.
FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.
Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.